{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:02:54Z","timestamp":1793638974349,"version":"4.5.1"},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,4,1]]},"DOI":"10.2169\/internalmedicine.5043-24","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:07:50Z","timestamp":1757542070000},"page":"1017-1022","source":"Crossref","is-referenced-by-count":9,"title":["Vanishing Bile Duct Syndrome Caused by a Treatment Regimen Including Avacopan for Microscopic Polyangiitis"],"prefix":"10.2169","volume":"65","author":[{"given":"Mako","family":"Hishinuma","sequence":"first","affiliation":[{"name":"Department of Nephrology, Fujita Health University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midori","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Faculty of Nursing, Fujita Health University School of Health Sciences, Department of Nephrology, Fujita Health University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Minatoguchi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Fujita Health University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Umeda","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Fujita Health University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigehisa","family":"Koide","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Fujita Health University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Fujita Health University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Yuzawa","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Fujita Health University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Minamiguchi","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Fujita Health University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naotake","family":"Tsuboi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Fujita Health University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Jayne DRW, Merkel PA, Schall TJ, Bekker P. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med 384: 599-609, 2021.","DOI":"10.1056\/NEJMoa2023386"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Draibe J, Espigol-Frigol\u00e9 G, Cid MC, et al. The real-world use and effectiveness of avacopan in routine practice for the treatment of ANCA vasculitis. First experiences in Spain. Rheumatology (Oxford) 64: 2019-2026, 2025.","DOI":"10.1093\/rheumatology\/keae534"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Zonozi R, Aqeel F, Le D, et al. Real-world experience with avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis. Kidney Int Rep 9: 1783-1791, 2024.","DOI":"10.1016\/j.ekir.2024.03.022"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Zimmermann J, Sonnemann J, Jabs WJ, et al. Avacopan in anti-neutrophil cytoplasmic autoantibodies-associated vasculitis in a real-world setting. Kidney Int Rep 9: 2803-2808, 2024.","DOI":"10.1016\/j.ekir.2024.07.007"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Uchida T, Fukui S, Iwamoto N, et al. Absence of glucocorticoids concomitant with avacopan and subsequent liver injury in antineutrophil cytoplasmic antibody-associated vasculitis. J Rheumatol 51: 1146-1148, 2024.","DOI":"10.3899\/jrheum.2024-0340"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Mori K, Shirai T, Mutoh T, et al. Drug-induced liver injury related to avacopan therapy. Rheumatology (Oxford) 63: 2533-2540, 2025.","DOI":"10.1093\/rheumatology\/keae689"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Tagami G, Yamaguchi M, Sugiyama H, et al. Efficacy and safety of avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis: a retrospective cohort study in Japan. BMC Rheumatol 9: 8, 2025.","DOI":"10.1186\/s41927-025-00456-4"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci 17, 2015.","DOI":"10.3390\/ijms17010014"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Miao S, Bekker P, Armas D, et al. Pharmacokinetic evaluation of the CYP3A4 and CYP2C9 drug-drug interaction of avacopan in 2 open-label studies in healthy participants. Clin Pharmacol Drug Dev 13: 517-533, 2024.","DOI":"10.1002\/cpdd.1389"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Lamba J, Hebert JM, Schuetz EG, Klein TE, Altman RB. PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenet Genomics 22: 555-558, 2012.","DOI":"10.1097\/FPC.0b013e328351d47f"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Zhang Y, Wang Z, Wang Y, et al. CYP3A4 and CYP3A5: the crucial roles in clinical drug metabolism and the significant implications of genetic polymorphisms. PeerJ 12: e18636, 2024.","DOI":"10.7717\/peerj.18636"},{"key":"12","unstructured":"12. Altraif I, Lilly L, Wanless IR, Heathcote J. Cholestatic liver disease with ductopenia (vanishing bile duct syndrome) after administration of clindamycin and trimethoprim-sulfamethoxazole. Am J Gastroenterol 89: 1230-1234, 1994."},{"key":"13","unstructured":"13. Yao F, Behling CA, Saab S, Li S, Hart M, Lyche KD. Trimethoprim-sulfamethoxazole-induced vanishing bile duct syndrome. Am J Gastroenterol 92: 167-169, 1997."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Cho HJ, Jwa HJ, Kim KS, Gang DY, Kim JY. Urosodeoxycholic acid therapy in a child with trimethoprim-sulfamethoxazole-induced vanishing bile duct syndrome. Pediatr Gastroenterol Hepatol Nutr 16: 273-278, 2013.","DOI":"10.5223\/pghn.2013.16.4.273"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Gonther S, Bachmann M, Goren I, et al. 3&apos;mRNA sequencing reveals pro-regenerative properties of <i>c5ar1<\/i> during resolution of murine acetaminophen-induced liver injury. NPJ Regen Med 7: 10, 2022.","DOI":"10.1038\/s41536-022-00206-x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Strey CW, Markiewski M, Mastellos D, et al. The proinflammatory mediators C3a and C5a are essential for liver regeneration. J Exp Med 198: 913-923, 2003.","DOI":"10.1084\/jem.20030374"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Yamaguchi H, Fujii N, Shimizu H. Persistent liver injury following avacopan discontinuation in antineutrophil cytoplasmic antibody-associated vasculitis: a rare case of liver biopsy in the chronic phase of liver injury. Mod Rheumatol Case Rep 9: 163-167, 2025.","DOI":"10.1093\/mrcr\/rxae071"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Nishino T, Tomori S, Haruyama M, Takahashi K, Mimaki M. A case of rapid avacopan-induced liver injury in pediatric granulomatosis with polyangiitis. Pediatr Nephrol 39: 2919-2922, 2024.","DOI":"10.1007\/s00467-024-06376-8"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kioi Y, Itotagawa E, Kawachi Y, et al. Case report: avacopan-induced severe liver injury with prolonged jaundice and lipoprotein X-induced dyslipidemia. Int J Rheum Dis 27: e15400, 2024.","DOI":"10.1111\/1756-185X.15400"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Shirota S, Shirai T, Mori K, et al. Comment on: a case of vanishing bile duct syndrome during treatment of microscopic polyangiitis with avacopan. Rheumatology (Oxford) 63: e149-e150, 2024.","DOI":"10.1093\/rheumatology\/kead561"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Kataoka H, Tomita T, Nakanowatari M, Kondo M, Mukai M. Gradual increase of avacopan dose with concomitant ursodeoxycholic acid use may help avoid the risk of C5a receptor inhibitor-induced liver injury in antineutrophil cytoplasmic antibody-associated vasculitis. Mod Rheumatol Case Rep 7: 444-447, 2023.","DOI":"10.1093\/mrcr\/rxad019"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Yamaguchi S, Yamazaki M, Kido T, et al. A case of vanishing bile duct syndrome during treatment of microscopic polyangiitis with avacopan. Rheumatology (Oxford) 63: e120-e122, 2024.","DOI":"10.1093\/rheumatology\/kead285"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Kojima K, Fukui S, Tanigawa M, et al. Severe prolonged liver abnormality with jaundice during treatment for granulomatosis with polyangiitis with rituximab and avacopan. Rheumatology (Oxford) 63: e101-e103, 2024.","DOI":"10.1093\/rheumatology\/kead509"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/7\/65_5043-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T03:55:05Z","timestamp":1775274905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/7\/65_5043-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5043-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"article-number":"5043-24"}}